Knowledge hub

The regulatory approval paves the way for ChestEye deployments in the Brazilian market. The application is already cleared for use in Europe and Australia. The Brazilian Health Regulatory Agency’s approval is one of Oxipit steps to increase global reach for company products.

AI medical imaging company Oxipit closed a $4.9M funding round led by Taiwania Capital, Practica Capital, and Coinvest Capital. Angel investors also participated in this round. The funding will help Oxipit advance its development of autonomous AI medical imaging applications and support market expansion into new geographic regions, with particular focus on the United Kingdom.

AI medical imaging company Oxipit expanded its ChestEye Quality product with quality assurance support for musculoskeletal X-rays, mammography images and CT scans. The new imaging modalities will follow the same AI-powered double reading workflow as with chest X-ray images. New Quality features will be showcased at RSNA 2022 annual meeting later this month.

Kaunas city polyclinic introduced Oxipit ChestLink AI application in their preventive health check up workflow. With ChestLink, which can automatically identify normal chest X-rays, healthy patients can be instantly sent home after the examination, without the need to wait for the study report at the polyclinic. Operating with 99.9% sensitivity, ChestLink can automatically report on 26% of all X-ray studies at Kaunas city polyclinic.

The new partnership aims to mitigate the risk associated with missed findings in CT medical imaging studies. The collaboration will combine Oxipit’s ChestEye Quality and contextflow’s SEARCH Lung CT products to identify missed findings in CT scans in near-real time. ECR 2022 will offer the first preview of the combined solution, and the first installation will be deployed at Leiden University Medical Center.

For the annual European Congress of Radiology meeting in Vienna, Oxipit has conducted a retrospective validation study from internal ChestEye Quality performance data at more than 10 pilot deployment institutions. The study concludes that 1 in 552 (0.18%) chest X-ray studies reported by a radiologist include clinically significant diagnostic mistakes. The vast majority - 78.46% - of the errors are missed findings of pulmonary nodules and lymphadenopathy.

Researchers in Finland released a preprint of a study on the application performance on real-world clinical data. In the study, the application analyzed 10.000 chest X-rays of Finnish primary health care patients. ChestLink software was able to identify normal studies with 99.8% sensitivity and and specificity of 36.4% with a minimal number of false negatives that would lead to effectively no compromise on patient safety and no critical findings missed by the software.

The companies conducted a joint pilot study, where Oxipit’s ChestEye Quality AI software is employed for improved pulmonary nodule detection. The software was deployed in two major primary care centers in Lithuania. With nearly 50.000 chest X-ray images analyzed over the course of 2021, ChestEye Quality helped to detect 82 additional clinically relevant nodule findings, potentially identifying additional early instances of lung cancer.

ChestLink is the first AI medical application to produce imaging study reports without any involvement from a human radiologist. This FAQ article explains 'everything ChestLink' in simple terms.

AI medical imaging application developer Oxipit was granted CE Class IIb certification for ChestLink autonomous AI imaging suite. The application autonomously reports on chest X-rays featuring no abnormalities without any involvement from a radiologist. It is the first regulatory approved AI medical imaging application to perform diagnostics autonomously.